Thermo Fisher Scientific Inc (TMO)
501.94
+2.33
(+0.47%)
USD |
NYSE |
Oct 04, 09:39
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 193.72B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -4.22% |
| Valuation | |
| PE Ratio | 34.31 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 4.506 |
| Price to Book Value | 4.428 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.35 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.7773 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 27.23% |
Profile
| Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2023 (revenue figures include some cross-segment revenue): analytical technologies (16% of sales); specialty diagnostic products (10%); life science solutions (24%); and lab products and services, which includes CRO services (54%). |
| URL | https://www.thermofisher.com |
| Investor Relations URL | https://ir.thermofisher.com |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Equity Style | Large Cap/Blend |
| Next Earnings Release | Oct. 26, 2023 (est.) |
| Last Earnings Release | Jul. 26, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Sep. 14, 2023 |
Ratings
Profile
| Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2023 (revenue figures include some cross-segment revenue): analytical technologies (16% of sales); specialty diagnostic products (10%); life science solutions (24%); and lab products and services, which includes CRO services (54%). |
| URL | https://www.thermofisher.com |
| Investor Relations URL | https://ir.thermofisher.com |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Equity Style | Large Cap/Blend |
| Next Earnings Release | Oct. 26, 2023 (est.) |
| Last Earnings Release | Jul. 26, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Sep. 14, 2023 |